Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 369 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hepatic Impairment Clear all
Completed No phase listed Observational Accepts healthy volunteers

Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort

NCT04097704
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment

NCT02120547
View directory record Official record
Conditions
Liver Insufficiency
Interventions
Cenicriviroc in mild liver impaired, Cenicriviroc in moderate liver impaired
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Jul 21, 2026, 10:25 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

NCT07324616
View directory record Official record
Conditions
Hepatic Impairment (HI)
Interventions
EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects

NCT03048448
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Fevipiprant
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Anaheim, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

NCT04604496
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
PF-06882961 20MG
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BG9928 in Subjects With Hepatic Impairment

NCT00858156
View directory record Official record
Conditions
Hepatic Impairment
Interventions
BG9928
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2010 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

NCT04016077
View directory record Official record
Conditions
Hepatic Impairment, Healthy Participants
Interventions
PF-06651600 30 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

NCT02296905
View directory record Official record
Conditions
Hepatic Impairment
Interventions
ABT-493, ABT-530
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

NCT02871570
View directory record Official record
Conditions
Moderate Hepatic Impairment, Normal Hepatic Function
Interventions
Rivipansel
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Results available

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

NCT01949545
View directory record Official record
Conditions
Solid Tumors, Hematologic Malignancies, Hepatic Impairment
Interventions
Carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Detroit, Michigan • Durham, North Carolina • Canton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Jul 21, 2026, 10:25 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

NCT03818672
View directory record Official record
Conditions
Severe Hepatic Impairment
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

NCT05404529
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Tavapadon
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2023 · Synced Jul 21, 2026, 10:25 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

NCT06442436
View directory record Official record
Conditions
Hepatic Impairment (HI)
Interventions
Nemtabrutinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 21, 2026, 10:25 PM EDT
Withdrawn No phase listed Observational

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

NCT05293938
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Obeticholic Acid 5 MG, Obeticholic Acid 10 MG, Standard of Care: UDCA
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

GT-032 Belapectin Hepatic Impairment

NCT04332432
View directory record Official record
Conditions
Hepatic Impairment
Interventions
belapectin
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
4
States / cities
Rialto, California • Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional

A Research Study on Etavopivat in Participants With and Without Liver Disease

NCT06336018
View directory record Official record
Conditions
Liver Diseases
Interventions
Etavopivat
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Orange, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function

NCT00831532
View directory record Official record
Conditions
Hepatic Failure
Interventions
Dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Orlando, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Jul 21, 2026, 10:25 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Pretomanid in Adults With Hepatic Impairment

NCT02422524
View directory record Official record
Conditions
Tuberculosis
Interventions
PA-824
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
St Louis, Missouri • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment

NCT01126086
View directory record Official record
Conditions
Hepatic Impairment
Interventions
otamixaban XRP0673
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Miami Gardens, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function

NCT02452801
View directory record Official record
Conditions
Hepatic Impairment
Interventions
ALKS 5461
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects

NCT01827657
View directory record Official record
Conditions
Hepatitis C
Interventions
GSK2336805
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 74 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001

NCT06619054
View directory record Official record
Conditions
Healthy Adults, Hepatic Impairment
Interventions
KP-001
Drug
Lead sponsor
Kaken Pharmaceutical
Industry
Eligibility
20 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional

A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems

NCT03842761
View directory record Official record
Conditions
Healthy, Hepatic Insufficiency
Interventions
BI 685509, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Jul 21, 2026, 10:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment

NCT03983161
View directory record Official record
Conditions
Healthy Volunteers, Hepatic Impairment
Interventions
Fedratinib
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Jul 21, 2026, 10:25 PM EDT